Since the COVID-19 outbreak, Chinese central SOEs have been making all-out efforts to support the battle against the virus not only in medical material production and development but also by transporting supplies to the front-lines, and in other ways as well.
China National Pharmaceutical Group Co., Ltd. (Sinopharm) has used its technology and capacity advantages to develop and produce nucleic acid diagnostic reagents soon after the outbreak of novel coronavirus.
- Timeline of China Releasing Information on COVID-19 and Advancing International Cooperation
- Beijing Requires 7 Extra Days of Health Monitoring for Inbound Travelers
- China Exports Over 224 Billion Masks to Assist Global COVID-19 Fight
- Vice-Premier Urges Persistent Epidemic Control Efforts in Winter, Spring